BC Extra | Sep 30, 2019
Company News

Sobi adding to U.S. presence, hematology pipeline via $915M Dova takeout

With the $915 million takeout of Dova Pharmaceuticals and a co-development deal with Sanofi in hemophilia, Sobi is continuing its push into the U.S. and strengthening its presence in hematology. Swedish Orphan Biovitrum AB (SSE:SOBI)...
BioCentury | Jun 29, 2019
Finance

Biotech backs down in 2Q19

In a reversal from 1Q19, biotech stocks across all market cap tiers fell in the second quarter, leading to a total loss of $22.3 billion. However, the year-to-date change in market cap remains well in...
BC Extra | Jun 28, 2019
Company News

June 27 Company Quick Takes: Zogenix soars; plus Gardasil, Darzalex, Soliris and more

Zogenix shares surge after agreement to resubmit Fintepla NDA  Zogenix Inc. (NASDAQ:ZGNX) closed up $8.24 (21%) to $47.65 on Thursday after the company announced it had reached an agreement with FDA to resubmit its NDA...
BC Extra | Apr 26, 2019
Company News

European regulatory roundup: CHMP opinions and a Portola approval

EMA's CHMP recommended a basket of approvals, including Dovato dolutegravir/lamivudine, Libtayo cemiplimab and two orphan therapies. Also Friday, the European Commission granted conditional approval to Ondexxya andexanet alfa from Portola Pharmaceuticals Inc. (NASDAQ:PTLA) to reverse...
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BC Week In Review | Aug 3, 2018
Clinical News

FDA approves Shionogi's thrombocytopenia drug

FDA approved Mulpleta lusutrombopag from Shionogi & Co. Ltd. (Tokyo:4507) to treat thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure. Mulpleta is the second drug to...
BC Extra | Jul 31, 2018
Company News

FDA approves Shionogi's thrombocytopenia drug

FDA approved Mulpleta lusutrombopag from Shionogi & Co. Ltd. (Tokyo:4507) to treat thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure. Mulpleta is the second drug to...
BioCentury | Jun 30, 2018
Finance

Hidden in the rough

Judicious stock picking was especially important in the second quarter, as 57% of global biotech stocks saw their equity values decline. Volatility continued to roil global markets during the period and additional uncertainty looms with...
BC Week In Review | May 25, 2018
Clinical News

Dova's thrombocytopenia drug gets its first approval from FDA

FDA approved Doptelet avatrombopag from the AkaRx Inc. subsidiary of Dova Pharmaceuticals Inc. (NASDAQ:DOVA) to treat thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure. The agency...
BC Extra | May 21, 2018
Company News

Dova's thrombocytopenia drug wins FDA approval

FDA approved Doptelet avatrombopag from the AkaRx Inc. subsidiary of Dova Pharmaceuticals Inc. (NASDAQ:DOVA) to treat thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure. The agency...
Items per page:
1 - 10 of 25